NASDAQ: BIMIBimi Holdings Inc Stock
$1.34-0.07 (-4.96%)
Updated Apr 18, 2024
BIMI Price
$1.34
Fair Value Price
N/A
Market Cap
$15.53M
52 Week Low
$0.66
52 Week High
$4.13
P/E
-0.52x
P/B
1.78x
P/S
1.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.85M
Earnings
-$14.76M
Gross Margin
40.5%
Operating Margin
-253.47%
Profit Margin
-252.4%
Debt to Equity
2.86
Operating Cash Flow
-$2M
Beta
0.52
Next Earnings
May 17, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BIMI Overview
BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Chongqing, the People's Republic of China.
Zen Score
–
Industry Average (20)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIMI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIMI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIMI is poor value based on its book value relative to its share price (1.78x), compared to the US Pharmaceutical Retailers industry average (1.14x)
P/B vs Industry Valuation
BIMI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIMI due diligence checks available for Premium users.
Be the first to know about important BIMI news, forecast changes, insider trades & much more!
BIMI News
Valuation
BIMI fair value
Fair Value of BIMI stock based on Discounted Cash Flow (DCF)
Price
$1.34
Fair Value
$3.27
Undervalued by
59.04%
BIMI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIMI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
-2.68x
Market
41.33x
BIMI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.78x
Industry
1.14x
BIMI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIMI's financial health
Profit margin
Revenue
$2.5M
Net Income
-$3.1M
Profit Margin
-124%
BIMI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BIMI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.0M
Liabilities
$24.9M
Debt to equity
2.86
BIMI's short-term assets ($24.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIMI's short-term assets ($24.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIMI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIMI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$0.0
Financing
$1.0M
BIMI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIMI vs Pharmaceutical Retailer Stocks
Bimi Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.